308 results on '"Karni, Arnon"'
Search Results
2. Real-World experience with efgartigimod in patients with myasthenia gravis
3. Associations of myeloid cells with cellular and humoral responses following vaccinations in patients with neuroimmunological diseases
4. Smartphone-based gait assessment for multiple sclerosis
5. Treadmill training with virtual reality to enhance gait and cognitive function among people with multiple sclerosis: a randomized controlled trial
6. Association Between Frailty and Free-Living Walking Performance in People With Multiple Sclerosis
7. Myasthenia gravis patients exhibiting an eyelid myotonia-like phenomenon
8. Olfactory function in Susac syndrome
9. BNT162b2 mRNA COVID-19 vaccine three-dose safety and risk of COVID-19 in patients with myasthenia gravis during the alpha, delta, and omicron waves
10. Fragmentation, circadian amplitude, and fractal pattern of daily-living physical activity in people with multiple sclerosis: Is there relevant information beyond the total amount of physical activity?
11. Susac’s syndrome – A new ocular finding and disease outcome
12. Differences in MS clinical and epidemiological characteristics between Ashkenazi and non-Ashkenazi Jewish patients in Israel: a retrospective single center study
13. Long-term Cognitive Outcomes in Susac Syndrome (P8-14.003)
14. Oral Administration of a Novel Small Molecule Blocks the BMP Canonical and the Non-canonical BMP2, BMP4, and BMP5 Signaling Pathways Ameliorates EAE Through Oligodendrogenesis Remyelination and Preservation of Axonal Integrity and Reduces Astrogenesis (P7-6.015)
15. Specific Blockade of Bone Morphogenetic Protein-2/4 Induces Oligodendrogenesis and Remyelination in Demyelinating Disorders
16. A wearable sensor identifies alterations in community ambulation in multiple sclerosis: contributors to real-world gait quality and physical activity
17. Fingolimod Increases Brain-Derived Neurotrophic Factor Level Secretion from Circulating T Cells of Patients with Multiple Sclerosis
18. Long-term cognitive outcomes in Susac syndrome: A case series
19. Natural and induced immunization against CCL20 ameliorate experimental autoimmune encephalitis and may confer protection against multiple sclerosis
20. High serum levels of BMP-2 correlate with BMP-4 and BMP-5 levels and induce reduced neuronal phenotype in patients with relapsing-remitting multiple sclerosis
21. Effect of ethnic origin and gender on the clinical manifestations of myasthenia gravis among the Jewish population in Israel
22. Erdheim-Chester disease presenting with chorea and mimicking IgG4-related disorder
23. Teaching NeuroImages: Hypertrophic olivary degeneration in a young man withPOLGgene mutation
24. Association between Frailty and Free-Living Walking Performance in People with Multiple Sclerosis
25. Peptide Analogs to Pathogenic Epitopes of the Human Acetylcholine Receptor α Subunit as Potential Modulators of Myasthenia Gravis
26. Thymus involvement in myasthenia gravis: Epidemiological and clinical impacts of different self-tolerance breakdown mechanisms
27. Characterization of patients with ocular myasthenia gravis — A case series
28. Increased occurrence of anti-AQP4 seropositivity and unique HLA Class II associations with neuromyelitis optica (NMO), among Muslim Arabs in Israel
29. Dysregulated production of leukemia inhibitory factor in immune cells of relapsing remitting multiple sclerosis patients
30. Expanding Our Knowledge of the Immunogenetic Characteristics of Anti-LGI1 Encephalitis—A Study of an Israeli Cohort Suggests Additional Significant HLA Associations With DQ Alleles
31. BNT162b2 mRNA COVID-19 Vaccine Three-Dose Safety and Risk of COVID-19 in Patients With Myasthenia Gravis
32. Treadmill training with virtual reality to enhance gait and cognitive function among people with multiple sclerosis: a randomized controlled trial
33. CTGF/CCN2 has a possible detrimental role in the inflammation and the remyelination failure in the early stages of multiple sclerosis
34. Elevated and dysregulated bone morphogenic proteins in immune cells of patients with relapsing–remitting multiple sclerosis
35. Five Years Analysis of anti-Glatiramer Acetate (GA) Antibodies in Patients with Relapsing Remitting Multiple Sclerosis Treated with GA Depot (P5-4.010)
36. High and dysregulated secretion of epidermal growth factor from immune cells of patients with relapsing-remitting multiple sclerosis
37. New Insights on DR and DQ Human Leukocyte Antigens in Anti-LGI1 Encephalitis
38. Low and dysregulated production of follistatin in immune cells of relapsing–remitting multiple sclerosis patients
39. Reduced production of noggin by immune cells of patients with relapsing–remitting multiple sclerosis
40. The Role of Molecular Imaging as a Marker of Remyelination and Repair in Multiple Sclerosis
41. Frailty and falls in people living with multiple sclerosis
42. Dysregulated neurotrophin mRNA production by immune cells of patients with relapsing remitting multiple sclerosis
43. Interferon-β therapy up-regulates BDNF secretion from PBMCs of MS patients through a CD40-dependent mechanism
44. Role of Immunosuppressive Therapy for the Treatment of Multiple Sclerosis
45. Low and dysregulated BDNF secretion from immune cells of MS patients is related to reduced neuroprotection
46. Central Nervous System Manifestation of IgG4-Related Disease
47. Specific Blockade of Bone Morphogenetic Protein-2/4 induces Oligodendrogenesis and Remyelination in Demyelinating Disorders (2042)
48. Glatiramer Acetate Depot (extended-release) phase IIa study in patients with Primary Progressive Multiple Sclerosis: safety and efficacy snapshot (1911)
49. Frailty and Falls in People Living With Multiple Sclerosis.
50. Increased Expression of Ephrins on Immune Cells of Patients with Relapsing Remitting Multiple Sclerosis Affects Oligodendrocyte Differentiation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.